TrianglePUBLICATIONS · 39437708
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Blood
- Publication date
- 2025 Jan 30
- First author
- Kumar A
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Kumar A
- type
- Author
- name
- Soumerai J
- type
- Author
- name
- Abramson JS
- type
- Author
- name
- Barnes JA
- type
- Author
- name
- Caron P
- type
- Author
- name
- Chhabra S
- type
- Author
- name
- Chabowska M
- type
- Author
- name
- Dogan A
- type
- Author
- name
- Falchi L
- type
- Author
- name
- Grieve C
- type
- Author
- name
- Haydu JE
- type
- Author
- name
- Johnson PC
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Kumar A
- type
- Author
- name
- Soumerai J
- type
- Author
- name
- Abramson JS
- type
- Author
- name
- Barnes JA
- type
- Author
- name
- Caron P
- type
- Author
- name
- Chhabra S
- type
- Author
- name
- Chabowska M
- type
- Author
- name
- Dogan A
- type
- Author
- name
- Falchi L
- type
- Author
- name
- Grieve C
- type
- Author
- name
- Haydu JE
- type
- Author
- name
- Johnson PC
- type
- Author
- bibliography ids
- nci-bib-31174b78bc37480d64701c92
- book metadata
- content sha256
- 34f7822b616c14d89d7b16a1b1c7b67c88abd65428d58a835c8c05ea1c90066b
- document type
- citation
- dois
- 10.1182/blood.2024025563
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:39437708
- immutable id
- pubmed:39437708@34f7822b616c14d89d7b16a1b1c7b67c88abd65428d58a835c8c05ea1c90066b
- journal
- abbreviation
- Blood
- issn electronic
- 1528-0020
- issn print
- 0006-4971
- issue
- 5
- name
- Blood
- nlm unique id
- 7603509
- pages
- 497-507
- volume
- 145
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 39437708
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- adb1a3e06f9526059035014bf99631be4b0589de12f5d6cf6c06c77285c99044
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2025 Jan 30
- precision
- day
- year
- 2025
- publication types
- Journal Article
- Clinical Trial, Phase II
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Preserved source evidence · Not medical advice